David A. Siegel Adma Biologics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 4,454,400 shares of ADMA stock, worth $77.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

4,454,400

Previous 4,654,600 4.3%

Holding current value

$77.7 Million

Previous $52 Million 71.11%

% of portfolio

0.22%

Previous 0.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$11.21 - $20.03 $2.24 Million - $4.01 Million	-200,200 Reduced 4.3%	4,454,400 $89 Million
Q2 2024 Aug 14, 2024	BUY	$5.98 - $11.18 $7.15 Million - $13.4 Million	1,195,000 Added 34.54%	4,654,600 $52 Million
Q1 2024 May 15, 2024	BUY	$4.4 - $6.74 $3 Million - $4.6 Million	682,000 Added 24.55%	3,459,600 $22.8 Million
Q4 2023 Feb 14, 2024	SELL	$3.08 - $4.52 $1.2 Million - $1.76 Million	-388,500 Reduced 12.27%	2,777,600 $12.6 Million
Q3 2023 Nov 14, 2023	BUY	$3.47 - $4.61 $1.41 Million - $1.87 Million	406,200 Added 14.72%	3,166,100 $11.3 Million
Q2 2023 Aug 14, 2023	BUY	$3.12 - $4.22 $2.34 Million - $3.17 Million	751,300 Added 37.4%	2,759,900 $10.2 Million
Q1 2023 May 15, 2023	BUY	$3.01 - $3.87 $4.35 Million - $5.6 Million	1,446,400 Added 257.27%	2,008,600 $6.65 Million
Q4 2022 Feb 14, 2023	BUY	$2.47 - $3.88 $1.32 Million - $2.08 Million	535,500 Added 2005.62%	562,200 $2.18 Million
Q3 2022 Nov 14, 2022	BUY	$2.03 - $2.86 $54,200 - $76,362	26,700 New	26,700 $65,000
Q1 2020 May 15, 2020	SELL	$1.5 - $4.59 $16,500 - $50,490	-11,000 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.89 - $5.15 $42,790 - $56,650	11,000 New	11,000 $44,000

Others Institutions Holding ADMA

# of Institutions

319

Shares Held

184M

Call Options Held

917K

Put Options Held

91.6K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.43B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account